RKDA Arcadia Biosciences, Inc.
Beverages · Nasdaq · SEC CIK 1469443 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.1%
TTM net income YoY-101.9%
TTM EPS YoY9.4%
Revenue 3-yr CAGR3.5%
Net income 3-yr CAGR—
Margins
Gross margin41.1%
Operating margin-68.9%
Net margin-202.1%
FCF margin—
EBITDA margin-68.7%
Returns
ROE-260.8%
ROA-153.9%
ROIC (approx.)-142.0%
Asset turnover0.76x
Leverage & solvency
Liabilities / assets49.0%
Debt / equity0.00x
Current ratio3.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-100.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.86M | $5.04M | $4.45M | $7.42M | $6.78M |
| Cost of revenue | $3.10M | $2.96M | $2.17M | $6.10M | $8.71M |
| Gross profit | $1.76M | $2.08M | $2.28M | $1.32M | -$1.93M |
| R&D expense | $9,000 | $53,000 | $64,000 | $1.51M | $3.89M |
| SG&A expense | $7.00M | $9.64M | $8.23M | $15.04M | $22.94M |
| Operating income | -$2.50M | -$3.65M | -$6.10M | -$14.01M | -$35.53M |
| Interest expense | — | — | — | — | $20,000 |
| Pretax income | -$2.33M | -$4.31M | -$5.32M | -$10.81M | -$16.13M |
| Income tax | $8,000 | $8,000 | $8,000 | $14,000 | $2,000 |
| Net income | -$2.34M | -$7.04M | -$13.98M | -$15.38M | -$14.66M |
| EBITDA | -$2.47M | -$3.59M | -$5.99M | -$13.57M | -$34.60M |
| EPS (basic) | -1.71 | -5.17 | -11.29 | -25.65 | -27.56 |
| EPS (diluted) | -1.71 | -5.17 | -11.29 | -25.65 | -27.56 |
| Weighted avg. shares (diluted) | 1.37M | 1.36M | 1.24M | 599,389 | 532,016 |
| Banking | |||||
| Net interest income | $221,000 | $782,000 | $695,000 | $289,000 | -$20,000 |
| Balance sheet | |||||
| Cash & equivalents | $259,000 | $4.24M | $6.52M | $20.64M | $28.68M |
| Short-term investments | $4.30M | $0 | $5.12M | $0 | — |
| Receivables | — | — | — | — | $1.37M |
| Inventory | $1.21M | $904,000 | $837,000 | $2.32M | $4.43M |
| Current assets | $6.36M | $9.24M | $14.97M | $25.40M | $35.39M |
| PP&E, net | $8,000 | $41,000 | $70,000 | $680,000 | $2.29M |
| Intangibles | $39,000 | $39,000 | $39,000 | $40,000 | $484,000 |
| Total assets | $6.55M | $13.52M | $19.70M | $28.92M | $43.92M |
| Current liabilities | $2.06M | $2.56M | $3.59M | $4.21M | $5.04M |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $0 |
| Total liabilities | $2.41M | $7.29M | $7.00M | $8.02M | $12.72M |
| Shareholders' equity | $4.14M | $6.22M | $12.84M | $21.03M | $31.09M |
| Net debt | — | — | — | — | -$28.68M |
| Shares outstanding | 1.37M | 1.36M | 1.29M | 616,079 | 554,609 |
| Cash flow statement | |||||
| Operating cash flow | -$4.74M | -$9.63M | -$15.29M | -$13.98M | -$25.87M |
| Capital expenditure | $0 | $16,000 | $5,000 | $72,000 | $1.01M |
| Free cash flow | -$4.74M | -$9.64M | -$15.30M | -$14.05M | -$26.88M |
| Investing cash flow | $750,000 | $7.34M | -$4.34M | $1.42M | $16.61M |
| Financing cash flow | $6,000 | $9,000 | $5.51M | $4.52M | $21.90M |
| Depreciation & amortization | $32,000 | $58,000 | $111,000 | $439,000 | $929,000 |
| Stock-based compensation | $234,000 | $512,000 | $717,000 | $1.11M | $1.54M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.